Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 4, 2009, Pages 283-289

  Obradovic, Slobodan D ^a,g   Antovic, Jovan P ^b   Antonijevic, Nebojsa M ^c   Ratkovic, Nenad G ^a   Vojvodic, Danilo V ^a   Subota, Vesna S ^d   Gligic, Branko Lj ^a   Obradovic, Dragana V ^a   Marinkovic, Eiena M ^e   Wallen, Hakan N ^f  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Clinical Centre of Serbia   (Serbia)

^d Military Medical Academy   (Serbia)

^e UNIVERSITY OF BELGRADE   (Serbia)

^f DANDERYD HOSPITAL   (Sweden)

^g KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Percutaneous coronary intervention; Platelet aggregation; Soluble cd40 ligand; Soluble p selectin; Thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CD40 LIGAND; CLOPIDOGREL; ENOXAPARIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PADGEM PROTEIN; TICLOPIDINE; TIROFIBAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; DRUG ELUTING STENT; ELECTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN SECRETION; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; AGED; CD40 LIGAND; FEMALE; HEART CATHETERIZATION; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; RISK FACTORS; THROMBOSIS;

EID: 67649549963     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328329f28c     Document Type: Article

References (28)

1. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, ef a/. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention insights into the STRATEGY Study. J Am Coll Cardio. 2006; 48:2178-2185.
2. Hochholzer W, Trenk D, Bestehorn H-P, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardio. 2006; 48:1742-1750.
3. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart. 2005; 26:804-847.
4. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulatio. 2007; 115:2196-2207.
5. Serebruany VL, Steinhubl SR, Berger PB, Malinin Al, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardio. 2005; 45:246-251.
6. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulatio. 2004; 109:3171-3175.
7. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Miïller- Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Natur. 1998; 391:591 -594.
8. Zhou L, Stordeur P, de Lavareille A, Thielemans K, Capel P, Goldman M, et al. CO40 engagement on endothelial cells promotes tissue- factor dependent procoagulant activity. Thromb Haemos. 1998; 79:1025-1028.
9. Santilli F, Basili S, Ferroni P, Davi G. CD40/CD40L system and vascular disease. Intern Emerg Me. 2007; 2:256-268.
10. Schönbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Patho. 2000; 156:7-14.
11. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vase Bio. 2000; 20:2322-2328.
12. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Re. 2003; 92:1041 -1048.
13. Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart. 2003; 24:2166-2179.
14. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl AcadSciUS. 1994; 91:8767-8771.
15. Merlen M, Thiagarajan P. P-seleclin expression on platelets determines size and stability of platelet aggregates. Circulatio. 2000; 102:1931-1936.
16. Hamm C, Braunwald E. Classification of unstable angina revisited. Circulatio. 2000; 102:118-122.
17. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events poststenting: results of the PREPARE POST-STENTING study. J Am Coll Cardio. 2005; 46:1820-1826.
18. Yan JC, Ding S, Liang Y, Ma GS, Zhu J, Feng Y, et al. Relationship between upregulation of CD40 system and restenosis in patients after percutaneous coronary intervention. Acta Pharmacol Si. 2007; 28:339-343.
19. Yan JC, Ma GS, Wu YG. The clinical implications of increased coexpression of CD40-CD40 ligand system and C-reactive protein in patients after percutaneous coronary intervention. Clinica Chimica Act. 2006; 374:140-141.
20. Turker S, Guneri S, Akdeniz B, Ozcan MA, Baris N, Badak O, et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardio. 2006; 97:198-202.
21. Cipollone F, Ferri C, Dosideri G, Paloscia L, Materazzo G, Mascellanli M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulatio. 2003; 108:2776-2782.
22. Yip H-K, Chang L-T, Sun C-K, Yang C-H, Hung W-H, Cheng C-l, et al. Impact of Clopidogre. on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardio. 2006; 97:192-194.
23. Azar RR, Badaoui G, Sarkis A, Kassab R, Salamé E, Klaymé S, et al. Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardio. 2005; 95:236-240.
24. Han SH, Koh KK, Quon MJ, Lee Y, Shin EK. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosi. 2007; 190:205-211.
25. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulatio. 2005; 111:2099-2106.
26. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, ef al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardio. 2006; 48:931 -938.
27. Wainstein MV, Bento da Silva DP, Ribeiro JP. Coronary stent implantation may seal the inflammatory response in patients with acute coronary syndromes. Int J Cardio. 2007; 130:503-504.
28. Malek LA, Grabowski M, Spiewak M, Ripiak KJ, Szpotanska M, Imiela T, et al. Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. Thromb Thrombolysi. 2007; 24:301 -305.